Pharmaceutical composition of salvia miltiorrhiza extractive, and use thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of composition and extract, applied in the pharmaceutical composition of Danshen extract and its application field
Inactive Publication Date: 2013-11-27
SHANDONG UNIV
View PDF0 Cites 2 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0014] As mentioned above, the salvianolic acid B and tanshinone IIA sodium sulfonate preparations currently used clinically use the main components of Salvia miltiorrhiza alone. The compatibility of danshen is also relatively limited. It can neither play the overall therapeutic effect of Danshen medicinal materials, nor can it reflect the synergistic effect of multi-component and multi-target compatibility.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0112] Example 1: Lyophilized preparation of salvianolic acid B, salvianolic acid A and sodium tanshinone IIA sulfonate (5:2:1)
[0113] Get 20g of salvianolic acid B, 8g of salvianolic acid A and 4g of sodium tanshinone IIA sulfonate in Example 1, add 32g of sodium ascorbate and 12.5g of mannitol, dissolve in 350ml of distilled water, and set the volume to 400ml, filter and sterilize, aseptic conditions The next part is packed in 100 vials, freeze-dried, and sealed under nitrogen to obtain the final product.
Embodiment 2
[0114] Example 2: Lyophilized preparation of salvianolic acid B, salvianolic acid A and sodium tanshinone IIA sulfonate (3:1:1)
[0115] Get 21g of salvianolic acid B, 7g of salvianolic acid A and 7g of sodium tanshinone IIA sulfonate in Example 1, add 7.4g of magnesium hydrogen phosphate, 35g of sodium ascorbate, and 12.5g of mannitol, dissolve in 250ml of distilled water, stir for 20 minutes, and constant volume to 300ml, filter out the insoluble matter, sterilize by filtration, subpackage in 100 vials under aseptic conditions, freeze-dry, and seal under nitrogen to obtain the product.
Embodiment 3
[0116] Example 3: Salvianolic acid B, salvianolic acid A and sodium tanshinone IIA sulfonate (9:3:2) freeze-dried powder injection
[0117] Take 18g of salvianolic acid B, 6g of salvianolic acid and 4g of sodium tanshinone IIA sulfonate, add 6g of magnesium hydrogen phosphate, 27g of sodium ascorbate, and 12.5g of mannitol, dissolve them in 250ml of distilled water, stir for 20 minutes, filter out insolubles, filter out sterilized, freeze-dried under aseptic conditions, the newly prepared powdery pharmaceutical composition is divided into 100 vials, sealed under nitrogen, and the product is obtained.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention relates to a pharmaceutical composition of salvia miltiorrhiza bge extractive, and the use of the pharmaceutical composition. The pharmaceutical composition is formed by combining salvianolic acid A or salvianolic acid B with tanshinone IIA sodium sulfonate or combining salvianolic acid A and salvianolic acid B with tanshinone IIA or sodium tanshinone IIA sulfonate. The therapeutical effect on myocardial infarction of the pharmaceutical composition is better than that of each constituent used singly, and the pharmaceutical composition can better achieve the therapeutical effects of multiple ingredients and multiple target points of salvia multiorrhiza bge and is used for preparing medicine for treating cardio-cerebrovascular diseases. According to the conventional manufacturing technology of pharmaceutics, the pharmaceutical composition can be processed into tablets, capsules, granules, freeze-drying preparation for injection, or freeze-drying preparation or powder for injection of carboxylate of the pharmaceutical composition.
Description
[0001] technical field [0002] This application is a divisional application of 201210044094.3. [0003] The present invention relates to a pharmaceutical composition of main components of salvia miltiorrhiza extract, in particular to the composition of salvianolic acid A, salvianolic acid B, tanshinone IIA or a chemical modification of tanshinone IIA, sodium tanshinone IIA sulfonate extracted and refined from salvia miltiorrhiza A pharmaceutical composition and its use. Background technique [0004] Salvia miltiorrhiza Bge, as a traditional traditional Chinese medicine, was first recorded in "Shen Nong's Materia Medica". Physicians of all dynasties compared Salvia miltiorrhiza to "one taste of salvia miltiorrhiza Bge, the same function as the four substances" ("Siwu" means "Siwu Decoction", Composed of Angelica, Rehmannia, Chuanxiong, and Paeoniae Alba), the magical effect of Danshen can be seen. According to the 2010 edition of Chinese Pharmacopoeia, Salvia miltiorrhiza...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more